FDA Approves Prandin, New Oral Treatment For Type II Diabetes
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




FDA Approves Prandin, New Oral Treatment For Type II Diabetes

BAGSVAERD, DENMARK -- December 23, 1997 -- The United States Food and Drug Administration (FDA) has approved Novo Nordisk A/S’s Prandin(TM) (repaglinide), a new agent for treatment of Type II diabetes.

Prandin is the first approved product in a new chemical class (meglitinide class) of orally-administered drugs for the treatment of Type II diabetes and was developed to manage meal-related (prandial) glucose loads. It is different from other oral anti-diabetic agents in structure and clearance. Its quick onset and short duration of action concentrates its effect around meal time glucose load, which is important to the treatment of Type II diabetes.

If a meal is skipped, so is the Prandin tablet; if a meal is added during the day, a tablet is added for that meal. Prandin stimulates insulin secretion from the beta cells of the pancreas by binding to sites on the beta cell. Prandin is minimally excreted by the kidney, which may be an advantage for patients (often elderly) who often suffer from decreased kidney function.

The agent is in-licensed by Novo Nordisk for worldwide development and marketing. The product trade name outside the U.S. will be NovoNorm .

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities